Relationship between serum testosterone level and hyperlipidemia and risk of prostate cancer

Abstract:

Objective：To explore the relationship between serum testosterone levels and hyperlipidemia and prostate cancer serum testosterone levels，by analyzing blood lipids and related indicators in 389 cases of prostate cancer and benign prostatic hyperplasia. Methods：Retrospective analysis was conducted in 389 cases of prostate biopsy or prostatectomy from January 2014 to March 2018. There were 117 cases of prostate cancer and 272 cases of benign prostatic hyperplasia，including 137 cases of hyperlipidemia. The data of age，free prostate specific antigen（fPSA），total prostate specific antigen（TPSA），f/PSA，serum testosterone，prostate volume（PV），and pathological diagnosis were collected. The study group was prostate cancer and thecontrol group was benign prostatic hyperplasia. Results：There were significant differences in age，TPSA，f/PSA and PV between the prostate cancer group and the benign prostatic hyperplasia group（P<0.05）. There was no significant difference between fPSA and serum testosterone（P>0.05）. In the low testosterone group and high testosterone group，there was no significant difference in testosterone between the two groups（P>0.05）. Among patients with hyperlipidemia，there was a statistically significant difference in hypercholesterolemia between prostate cancer and benign prostatic hyperplasia（P<0.05）. There was no statistically significant difference between high triglyceride and low-high density lipoprotein（P>0.05）. Conclusion：There is no clear relationship between serum testosterone levels and the risk of prostate cancer. Hypercholesterolemia may increase the risk of prostate cancer.